Anti-Obesity Drugs and The Coming Battle Over Utilization Management (video)

My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs.

As I explain, this growth will challenge payer and channel economics, while boosting profits for patient reimbursement hub businesses and pharmacy benefit managers (PBMs).

The widespread use of these products will also lead to greater scrutiny of utilization management—the tools that PBMs use to influence and manage prescription costs.

If this clip whets your appetite for more, register to watch a replay of the full 100 minute Drug Channels Outlook 2024 video webinar.

Click here to sign up for The Drug Channels 2024 Video Webinar Series. My first webinar will be on April 5, 2024.

Click here if you can’t see the video above.